IBA Signs Contract to Install Cyclone® 70 System in Arizona, USA

Cyclotron to be dedicated to the production of radiopharmaceuticals for diagnosing and treating critical illnesses worldwide

Louvain-la-Neuve, Belgium, June 8th 2018 - IBA (Ion Beam Applications S.A., EURONEXT), a world’s leading provider of solutions for the diagnosis and treatment of cancer, today announces it has signed a formal contract with the Arizona Isotopes Science Research Corp. (AZI) to install a Cyclone® 70 system in Arizona, USA. The installation of the system is worth between $16 and $20 million to IBA and the project is fully financed.

Bruno Scutnaire, Head of RadioPharma Solutions at IBA, commented: “We are delighted to see the Arizona Isotopes Science Research Corp. selecting our Cyclone® 70 system. This will enable the continuous production of isotopes used in the diagnosis of cardiovascular diseases and other critical illnesses. IBA is the only provider of radiopharmaceutical cyclotrons with the expertise and experience to construct such a high energy system.”

“We selected IBA for its leading technology and unique know-how in developing high energy 70 MeV cyclotrons,” said Dr Sheldon Trubatch, AZI Corporate Secretary. “IBA’s expertise will allow us to reach our objectives of supplying medical isotopes for the diagnosis and treatment of critical illnesses worldwide.”

The Cyclone® 70 is a high energy and high current proton industrial cyclotron. IBA has sold three other Cyclone® 70 systems to date: the Cyclone® 70 (multiparticle version cyclotron) which has been fully operational for radioisotope production and research in France (Arronax project, Nantes) since 2011; the Cyclone® 70 at Zevacor Molecular in the USA is fully operational since 2015; and a third Cyclone®70 currently under installation in Moscow, Russia.

***ENDS***

About IBA Radiopharma Solutions
Based on longstanding expertise, IBA RadioPharma Solutions supports hospitals and radiopharmaceutical distribution centers with their in-house radioisotopes production by providing them with global solutions, from project design to the operation of their facility. In addition to high-quality technology production equipment, IBA has developed in-depth experience in setting up GMP
radiopharmaceutical production centers. For more info, please visit our website: www.iba-radiopharmasolutions.com

About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at www.iba-worldwide.com

About Arizona Isotopes Science Research Corp.
The Arizona Isotopes Science Research Corp. (AZI) is devoted to providing the isotopes necessary for the production of radiopharmaceuticals used for diagnosing and treating cancer, heart disease, and other life-threatening medical conditions. AZI has begun implementing its goals by purchasing a Cyclone® 70 cyclotron from IBA initially to generate Strontium-82 (Sr-82). AZI is working with universities in the state of Arizona along with other universities and research organizations elsewhere to develop research into the development and use of other radionuclides to address medical issues. AZI has assembled a globally recognized team of technical, legal and business professionals with in-depth familiarity in international business development and management, the US Department of Energy, US Nuclear Regulatory Commission and the US National Institutes of Health programs and policies for medical isotopes.

For further information, please contact:

IBA
Soumya Chandramouli
Chief Financial Officer
+32 10 475 890
Investoorrelations@iba-group.com

Thomas Ralet
Head of Corporate Communication
+32 10 475 890
communication@iba-group.com

For media and investor enquiries:
Consilium Strategic Communications
Amber Fennell, Matthew Neal, Ivar Milligan
+44 (0) 20 3709 5700
IBA@consilium-comms.com

Press release | June 8th, 2018